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Abstract: Recent times have seen an increasing move towards harnessing the health-promoting
benefits of food and dietary constituents while providing scientific evidence to substantiate their
claims. In particular, the potential for bioactive protein hydrolysates and peptides to enhance health in
conjunction with conventional pharmaceutical therapy is being investigated. Dairy-derived proteins
have been shown to contain bioactive peptide sequences with various purported health benefits,
with effects ranging from the digestive system to cardiovascular circulation, the immune system
and the central nervous system. Interestingly, the ability of dairy proteins to modulate metabolism
and appetite has recently been reported. The ghrelin receptor (GHSR-1a) is a G-protein coupled
receptor which plays a key role in the regulation of food intake. Pharmacological manipulation of
the growth hormone secretagogue receptor-type 1a (GHSR-1a) receptor has therefore received a lot
of attention as a strategy to combat disorders of appetite and body weight, including age-related
malnutrition and the progressive muscle wasting syndrome known as cachexia. In this study,
a milk protein-derivative is shown to increase GHSR-1a-mediated intracellular calcium signalling
in a concentration-dependent manner in vitro. Significant increases in calcium mobilisation were
also observed in a cultured neuronal cell line heterologously expressing the GHS-R1a. In addition,
both additive and synergistic effects were observed following co-exposure of GHSR-1a to both the
hydrolysate and ghrelin. Subsequent in vivo studies monitored standard chow intake in healthy male
and female Sprague-Dawley rats after dosing with the casein hydrolysate (CasHyd). Furthermore,
the provision of gastro-protected oral delivery to the bioactive in vivo may aid in the progression
of in vitro efficacy to in vivo functionality. In summary, this study reports a ghrelin-stimulating
bioactive peptide mixture (CasHyd) with potent effects in vitro. It also provides novel and valuable
translational data supporting the potential role of CasHyd as an appetite-enhancing bioactive. Further
mechanistic studies are required in order to confirm efficacy as a ghrelinergic bioactive in susceptible
population groups.
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1. Introduction
The potential health benefits of the bioactive fragments which exist within the matrix of many
food and dietary components have long been known [1]. Milk is one of the richest sources of bioactive
fragments and there is a growing body of evidence that these can have positive effects on appetite and
metabolism [2–5]. Many of these bioactives are proven to have various health benefits, spanning the
digestive, endocrine, cardiovascular, immune and nervous systems [6,7]. Identification and isolation
of these bioactives, as well as elucidating their pharmacodynamic parameters are necessary to realise
functional applications [8]. The utilisation of dairy-derived bioactives in appetite-related disorders is
now becoming increasingly apparent [1,2]. The ability of a bioactive to enhance satiety and decrease
food intake in vivo has been shown [4]. Conversely, recent work has also shown a whey protein
isolate to reduce the expression of satiating genes in the hypothalamus and to increase food intake in
rodents [5]. However, more translational studies are required to provide insights into the merits and
mechanisms of milk-derived bioactives to treat appetite-related disorders.
The endogenous hormone ghrelin, a 28 amino acid peptide is one of the key factors involved
in food intake regulation [9]. The ghrelin receptor growth hormone secretagogue receptor-type 1a
(GHSR-1a) has thus been a therapeutic target for disorders of appetite [10,11]. In particular, the focus
has been on individuals with poor appetite secondary to co-morbid conditions such as cardiovascular
disease, respiratory disease and cancer, who can suffer an advanced form of ‘wasting syndrome’
known as cachexia [12]. Though ghrelin and synthetic ghrelin ligands have shown robust effects on
food intake in humans for the treatment of cancer-related cachexia, the initiation of pharmaceutical
therapy is restricted to these patients and would not be routine in mildly reduced appetites, such as
those seen in ageing populations [13–15]. Nevertheless, a ubiquitous decline in ghrelin levels with age
is a major contributory factor to appetite reductions and weight loss [16]. Poor nutritional status in
elderly patients is a complicating factor for chronic diseases and results in prolonged hospital stays,
lessened independent living and poorer response to treatment, leading to an overall greater burden
on global health infrastructures and poorer clinical outcomes [17]. Age-related appetite loss hence
represents an important, unmet, clinical need. Given the lack of suitable pharmacotherapy and the
growing role of nutraceutical science, we suggest the potential role of a bioactive ghrelin agonist to
help delay the onset of a cachectic state due to comorbid illnesses.
Bioactives that augment the ghrelin system have previously yielded anecdotal evidence of
increased appetite, which has since been substantiated by animal and human studies. Rikkunshito
(RKT), a long-standing traditional Japanese herb has the ability to function as a ghrelin agonist [18].
RKT has been shown to reduce weight loss and increase food intake in mouse models of wasting
syndrome [19,20], while a retrospective analysis of cancer patients showed increased median survival
time in patients receiving concomitant RKT with their treatment [18]. Chin-shin oolong tea, a popular
tea in Taiwan, was perceived to induce hunger, and subsequently was shown to increase food intake in
rats [21]. In vitro, an isolate from emoghrelin heshouwu, a Chinese traditional medicine, was shown
to activate the GHSR-1a and stimulate growth hormone (GH) secretion in vitro, supporting a claim for
its perceived therapeutic efficacy as an anti-ageing supplement [22]. Furthermore, an extract from the
herbal medicine Harpagophytum procumbens was shown to act on the GHSR-1a and modulate appetite
in an in vivo mouse model [23].
There is an impetus to provide dietary-incorporated, scientifically validated interventions for
poor appetite at an early point, rather than initiating late-stage pharmaceutical therapy which is
often expensive, ineffective and not without side-effects. The proactive use of nutraceutical therapy
as a preventative or complementary approach to traditional pharmacotherapy has been recently
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discussed [24,25]. Milk is one of the primary sources of bioactive fragments for nutraceuticals,
many of which have purported health benefits in relation to appetite and metabolism. However,
further bioactive identification, enrichment and incorporation into appropriate delivery systems
is required [26]. Our screening platform revealed the dairy hydrolysate (CasHyd), a mixture of
peptides produced by the enzymatic cleavage of casein, which potently activates the GHSR-1a in vitro.
We demonstrate additive and synergistic effects of the hydrolysate with ghrelin. We also investigate the
potential of this bioactive peptide mixture to function as an appetite stimulant in vivo under different
modes of administration. This study thus represents an interesting, novel translational investigation of
a dairy-derived appetite-stimulating bioactive targeting the GHSR-1a with potential for inclusion as a
functional food ingredient in population groups with poor appetite who may be at risk of developing
malnutrition and cachexia.
2. Results
2.1. Activity of CasHyd on Ghrelin-Receptor Overexpressing-Cell Line
The activity of the casein-derived hydrolysate, CasHyd, on the GHSR-1a was analysed using an
intracellular Ca2+ mobilisation assay, as a measure of downstream GHSR-1a signalling activation [27],
in HEK293A cells stably expressing the GHSR-1a tagged with an enhanced green fluorescent protein
(GHSR-1a-EGFP) (Figure 1).
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(HEK293A-5HTR2C -VSV) expressing cells. Intracellular Ca2+ increase is depicted as a percentage of 
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Table 1. Activity of CasHyd and Ghrelin on GHSR-1a overexpressing HEK293A cells. 
Compound EC50 Emax 1 
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CasHyd 0.27 mg/mL 148.9% 
1 Intracellular Ca2+ increase reported as a percentage of maximal Ca2+ influx in relative fluorescence 
unit (RFU) as elicited by control (3.3% FBS). 
CasHyd stimulated calcium mobilisation in cells expressing GHSR-1a in a concentration-
dependent manner, with the EC50 = 0.27 mg/mL and efficacy (Emax) reaching 148.9%. The potency of 
CasHyd was 1000-fold lower than that for the endogenous receptor ligand, ghrelin (EC50 = 0.25 
µg/mL, Emax = 132.5%) (Table 1). Considering CasHyd is a mixture of different peptides not all of 
which are likely to elicit bioactivity, the activation found here on the GHSR-1a indicates promising 
Figure 1. (A) Concentration response curve of casein-deri drolysate. Concentration response
curve for the casein-derived hydrolysate, CasHyd, red in growth hormon s cretagogue
receptor-type 1a (GHSR-1a) overexpressed in HEK2 lls; (B) Activity of CasHyd in wild-type
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Table 1. Activity of CasHyd and Ghrelin on GHSR-1a overexpressing HEK293A cells.
Compound EC50 Emax 1
Ghrelin 0.25 µg/mL (74 nM) 132.5%
CasHyd 0.27 mg/mL 148.9%
1 Intracellular Ca2+ increase reported as a percentage of maximal Ca2+ influx in relative fluorescence unit (RFU) as
elicited by control (3.3% FBS).
CasHyd stimulated calcium mobilisation in cells expressing GHSR-1a in a concentration-dependent
manner, with the EC50 = 0.27 mg/mL and efficacy (Emax) reaching 148.9%. The potency of
CasHyd was 1000-fold lower than that for the endogenous receptor ligand, ghrelin (EC50 = 0.25
µg/mL, Emax = 132.5%) (Table 1). Considering CasHyd is a mixture of different peptides not
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all of which are likely to elicit bioactivity, the activation found here on the GHSR-1a indicates
promising ability to modulate the receptor. Efficacy of CasHyd was expressed as a percentage of the
maximum response obtained by the positive control (3.3% fetal bovine serum, FBS, Emax = 100%).
Interestingly, no concentration-dependent Ca2+ mobilisation was observed in wild-type HEK293A
cells (HEK293A-WT) not expressing the GHSR-1a. Furthermore, no activity was observed in
5HT2C (HEK293A-5HTR2C) receptor-expressing cell line, nor in the edited from of the 5HTR2C,
(HEK293A-5HTR2C-VSV), compared to treatment with control (FBS), which gives maximal intracellular
Ca2+ mobilisation in all tested cell lines. Food intake and adiposity are altered in vivo when the 5-HT2C
receptor RNA is fully edited, suggesting a potential role for 5-HT2C editing in eating disorders [28].
Together, these results show, to our knowledge for the first time, the promising potential of a casein
hydrolysate, CasHyd, to modulate the GHSR-1a.
2.2. Calcium Imaging on Ghrelin-Receptor Overexpressing-Cell Line
Next, the GHS-R1a mediated calcium response of the HEK-GHSR-1a cells to ligand exposure was
investigated using calcium imaging. Following addition of 500 nM ghrelin, an increased fluorescence
peak is observed indicating calcium influx due to treatment. This calcium influx is also observed upon
the acute addition of CasHyd (1.5 mg/mL), but to a lesser extent than was seen upon ghrelin addition
(Figure 2A). Calcium influx is evident through the shift in fluorescence from pink to blue (Figure 2B),
indicating calcium release from intracellular stores resulting in an excitation shift from 340 nm to
380 nm. This further corroborates the calcium mobilisation results obtained.
Int. J. Mol. Sci. 2018, 19, x 4 of 21 
 
ability to modulate the receptor. Efficacy of CasHyd was expressed as a percentage of the maximum 
response obtained by the positive control (3.3% fetal bovine serum, FBS, Emax = 100%). Interestingly, 
no concentration-dependent Ca2+ mobilisation was observed in wild-type HEK293A cells (HEK293A-
WT) not expressing the GHSR-1a. Furthermore, no activity was observed in 5HT2C (HEK293A-
5HTR2C) receptor-expressing c ll line, nor in the edited from of the 5HTR2C, (HEK293A-5HTR2C-VSV), 
c mpared to tre tm nt with control (FBS), which gives maximal intracellular Ca2+ m bilisation in all 
tested cell lines. Food intake and adiposity are altered in vivo when the 5-HT2C receptor RNA is fully 
edited, suggesting a potential role for 5-HT2C editing in eating disorders [28]. Together, these results 
show, to our knowledge for the first time, the promising potential of a casein hydrolysate, CasHyd, 
to modulate the GHSR-1a. 
2.2. Calcium Imaging on Ghrelin-Receptor Overexpressing-Cell Line 
Next, the GHS-R1a mediated calcium response of the HEK-GHSR-1a cells to ligand exposure 
was investigated using calcium imaging. Following addition of 500 nM ghrelin, an increased 
fluorescence peak is observed indicating calcium influx due to treatment. This calcium influx is also 
observed upon the acute addition of CasHyd (1.5 mg/mL), but to a lesser extent than was see  upon 
ghrelin add tion (Fig re 2A). Calcium influx is evident thro gh the shift in fluorescence from pink to 
blue (Figure 2B), indicating calcium release from intracellular stores resulting in an excitation shift 
from 340 nm to 380 nm. This further corroborates the calcium mobilisation results obtained. 
 
 
Figure 2. Specific activation of heterologously expressed GHSR-1a in HEK293A cell line. (A) Calcium 
imaging of human embryonic kidney (HEK) cells heterologously expressing the GHS-R1a. Cells were 
seeded for 48 h into wells at a density of 2.0 × 105 cells/mL, and loaded for 1 h with the UV-excitable 
fluorescent calcium indicator, Fura-2AM, and the 340 nm/380 nm ratio was recorded after addition of 
500 nM ghrelin or 1.5 mg/mL CasHyd. (B) Calcium influx is evident through the shift in fluorescence 
from pink to blue (40× magnification). Traces represent the average of three independent experiments, 
error bars are indicative of SEM. 
























Figure 2. Specific activation of heterologously expressed GHSR-1a in HEK293A cell line. (A) Calcium
imaging of human embryonic kidney (HEK) cells heterologously expressing the GHS-R1a. Cells were
seeded for 48 h into wells at a density of 2.0 × 105 cells/mL, and loaded for 1 h with the UV-excitable
fluorescent calcium indicator, Fura-2AM, and the 340 nm/380 nm ratio was recorded after addition of
500 nM ghrelin or 1.5 mg/ L CasHyd. (B) Calcium influx is evident through the shift in fluorescence
from pink to blue (40× magnification). Traces represent the average of three independent experiments,
error bars are indicative of SEM.
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2.3. HPLC Characterisation of CasHyd
Size exclusion chromatography carried out on the whole unhydrolysed protein, sodium caseinate
(NaCas) versus the hydrolysate, CasHyd, shows no overlap in the molecular weight distribution after
enzymatic hydrolysis (Figure 3). The unhydrolysed parent protein, NaCas, showed 85.9% of total
proteins to be >25 kDa molecular weight, whereas 86.0% of CasHyd is below 1 kDa in size (Table 2).
This shows the extent of hydrolysis which takes place, yielding a mixture of vastly different peptide
fractions to the parent casein protein. In addition, the high level of hydrolysis of CasHyd, yielding a
majority of peptides <1 kDa, is likely to contribute to the observed bioactivity of GHSR-1a modulation.
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Figure 3. Size exclusion HPLC for CasHyd fraction compared with parent casein protein. Molecular
weight distribut on of CasHyd and parent prot i , sodium ca einate (N Cas), expressed as absorbance
over time on HPLC chromatogram.
Table 2. Molecular weight distribution of NaCas and CasHyd.
Molecular Weight Retention Time (min) NaCas (% Area) CasHyd (% Area)
>25 kDa <14.66 85.9 0.0
25–10 kDa 14.66–17.26 13.1 0.0
10–5 kDa 17.26–19 1.0 0.0
5–1 kDa 19–21.35 0.0 14.0
<1 kDa >21.35 .0 86.
2.4. GHSR-1a Activation by CasHyd in Neuronal Cells In Vitro
Next, the activity of CasHyd was assessed in the neuroblastoma cell line, SHSY-5Y, engineered to
overexpress the GHS-R1a as a native receptor using lentiviral vectors. A calcium mobilisation response
following exposure to the endogenous ligand, ghrelin, as well as the dairy-derived hydrolysate,
CasHyd, was observed in both engineered cell lines (Figure 4).
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Figure 4. Specific activation of GHS-R1a r ceptor in vitro. Both CasHyd (3 g/mL) and ghrelin
(100 nM) elicited a GHS-R1a-eGFP (enhanced green fluorescent protein) mediated calcium influx in
both HEK cells stably expressing GHSR1a-eGFP, and the neuronal-like SHSY-5Y cell line generated to
express S 1a-e FP using lentiviral vectors. raph represents the ean SEM of a representative
experi ent. Each concentration was carried out in triplicate. Intracellular calcium increase as
nor alised to axi al calciu increase as elicited by control (100 n ghrelin).
2.5. Additive and Synergistic Effects of the Dairy-Derived Hydrolysate on Ghrelin-Mediated GHSR-1a
Activation
Potential additive or synergistic effects between ghrelin and the dairy-derived hydrolysate on
GHS-R1a activation were investigated. Cells stably expressing the GHSR1a were exposed to different
concentrations of ghrelin (100–3.7 nM) and CasHyd (3–0.5 mg/mL). Increases in intracellular calcium
could be observed following all concentrations of hydrolysate and a dose dependent calcium influx for
ghrelin (Figure 5). However, no synergistic effects were observed. A small additive effect was observed
for cells treated with a suboptimal concentration of ghrelin (33 nM) and all three concentrations of
CasHyd but this did not reach statistical significance. However, when analysing the effect on calcium
mobilisation using lower concentrations of CasHyd (0.1 and 0.03 mg/mL), clear additive effects could
be observed with 30 and 10 nM ghrelin (Figure 6A). In addition, additive calcium mobilisation was
observed following co-treatment of 0.3 mg/mL CasHyd and 3.3 or 1.1 nM ghrelin (Figure 6B). Moreover,
synergistic effects were observed when cells were co-treated with the two lowest concentrations of
CasHyd (0.1 or 0.03 mg/mL) and ghrelin (3.3 and 1.1 nM).
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Figure 5. Additive GHS-R1a activation following co-treatment of ghrelin and CasHyd. Additive
calcium mobilisation is observed following co-treatment of HEK cells stably expressing the
GHS-R1a-eGFP with 33 nM of ghrelin and CasHyd. Graph represents the mean ± SEM of a
representative experiment of three independent experiments. Each concentration reported was carried
out in triplicate. Intracellular calcium increase was normalised to maximal calcium increase as elicited
by control (100 nM ghrelin). Statistically significant differences were calculated using a one-way
analysis of variance (ANOVA) followed by the Bonferroni post-hoc test for multiple comparisons and
are depicted as *** p < 0.001, ** p < 0.01 and * p < 0.05.
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Figure 6. Additive and synergistic effects of GHS-R1a activation following co-treatment of ghrelin
and CasHyd. Additive and synergistic effects are observed following co-treatment of HEK cells
stably expressing the GHS-R1a with hydrolysate and 30 nM or 10 nM ghrelin (A), or hydrolysate
and 3.3 nM or 1.1 nM ghrelin (B). Intracellular calcium increase was normalised to the maximum
calcium increase as el ited by control (100 nM ghrelin). Grap s represent the mean ± SEM of a
representative experiment of three independent experiments, with each concentration point performed
in triplicate. Statistically significant differences of combination treatment indicating an additive effect
were calculated using a one-way analysis of variance (ANOVA) followed by the Bonferroni post-hoc
test for multiple omparison and are depict d as *** p < 0.001, ** p <0.01 and * p <0. 5. Statistically
significant differences of a synergistic effect are depicted as; $ p < 0.001, & p < 0.01 and # p < 0.05.
Int. J. Mol. Sci. 2018, 19, 2780 8 of 21
2.6. Cumulative Food Intake Studies after Intraperitoneal Injection of Peptide Solution
In food intake studies following an intraperitoneal injection (IP) of CasHyd 50·mg kg−1 in 0.9%
saline, or control, there were no significant differences noted in the amount of food consumed between
groups, normalised to body weight (Figure 7). Examination of individual time bins yielded no overall
differences at any timepoint. Hence, we conclude that CasHyd is not effective as an appetite stimulant
with this mode of delivery.
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Figure 7. Cumulative food intake following intraperitoneal administration of dairy-derived peptide
hydrolysate. Cumulative food intake (CFI) (regular chow) intake in male (A) and female (C)
Sprague-Dawley rats was determined following intraperitoneal injection with 50 mg·kg−1 body weight
of CasHyd over 6 h. The food intake per time bin is also illustrated for males (B) and females (D). Data
presented as mean ± SEM.
2.7. Cumulative Food Intake Studies after Oral Administration of Peptide Solution
In cumulative food intake (CFI) studies following an oral gavage of a 50 mg·kg−1 dose of peptide
solution, there were significant increases noted in the amount of food consumed relative to control in
both males and females, normalised to body weight (males, p = 0.013, females p = 0.021; Huyn-Feldt
sphericity correction) (Figure 8). Pairwise comparisons also revealed trends at 3 h and 5 h post dose,
and a significant increase at 4 h compared to control for the female cohort. The most significant change
in food intake was in the 5–6 h time bin for both males and females (Figure 8B,D). The GHSR-1a
is located on vagal nerve terminals in the gastrointestinal tract, throughout the small and large
intestine [29], potentially explaining the increased efficacy of the oral route versus IP via potential local
GHSR-1a stimulation.




Figure 8. Cumulative food intake following oral administration of unencapsulated dairy protein-
derived hydrolysates. Food (regular chow) intake in male (A) and female (C) Sprague-Dawley rats 
was determined following oral gavage with 50mg kg−1 body weight of CasHyd over 6 h. Cumulative 
food intake (CFI) was determined at regular intervals after oral gavage. The food intake per time bin 
is also illustrated (B,D). Graphs represent the mean ± SEM. Statistical significance was determined 
using repeated measures ANOVA and estimation of parameters for food intake. Pairwise 
comparisons were carried out using Tukey’s post-hoc test, while independent samples t-tests were 
used for each individual time bin; statistical significance is depicted as * p < 0.05. 
2.8. pH Susceptibility of CasHyd 
CasHyd was exposed to increasing levels of acidity for a period representative of the minimum 
amount of time required for gastric emptying (30 min [30]). A pH-dependent loss in peptide activity 
is observed for CasHyd, confirming the need to develop a gastro-resistant formulation to minimise 
exposure to gastric acid before progression to further in vivo efficacy studies (Figure 9). 
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Figure 8. Cumulative food intake following oral administration of unencapsulated dairy
protein-derived hydrolysates. Food (regular chow) intake in male (A) and female (C) Sprague-Dawley
rats was determined following oral gavage with 50mg kg−1 body weight of CasHyd over 6 h.
Cumulative food intake (CFI) was determined at regular intervals after oral gavage. The food intake
per time bin is also illustrated (B,D). Graphs represent the mean ± SEM. Statistical significance was
determined using repeated measures ANOVA and estimation of parameters for food intake. Pairwise
comparisons were carried out using Tukey’s post-hoc test, while independent samples t-tests were
used for each individual time bin; statistical significance is depicted as * p < 0.05.
2.8. pH Susceptibility of CasHyd
CasHyd was exposed to increasing levels of acidity for a period representative of the minimum
amount of time required for gastric emptying (30 min [30]). A pH-dependent loss in peptide activity
is observed for CasHyd, confirming the need to develop a gastro-resistant formulation to minimise
exposure to gastric acid before progression to further in vivo efficacy studies (Figure 9).
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Figure 9. -1a agonist, CasHyd, isplays pH dependent activity. Reduction in hydrolysate-mediated
GHSR-1a activation following exp sure to acidic pH confirms the eed for an oral delivery mechanism.
The graph represents t re ind pendent experiments carried out i at least triplicate (control = CasHyd
n t exposed to acidic pH, RFU = relative fluorescenc units).
2.9. Delivery System (Pellet) Characterisation Work
Since CasHyd is susceptible to acidic pH, the peptide mixture was incorporated into a
gastro-protected delivery system (coated pellets) in order to minimise exposure to the stomach in vivo.
Simulated release profile assessment of CasHyd from the formulation was carried out in vitro in order
to assess whether the coating applied to the pellets was able to delay release. USP Type 1 (basket)
dissolution studies were carried out in gastric conditions (simulated gastric fluid, SGFsp, pH 1.2) in
order to confirm a delayed release of peptide from the pellets. Pellets displayed a delayed release of
peptide load over 60 min, confirming the functionality of the delivery system (Figure 10).
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Figure 10. Dissolution study of gastro-protected CasHyd pellets. USP type 1 (basket) dissolution
studies (50 rpm, 37.5 ◦C) showed gastro-protected release in simulated conditions (simulated gastric
fluid sine pepsin, SGFsp; pH 1.2).
2.10. GHSR-1a Activity of Peptide Post-Encapsulation
Due to the likely fragile nature of the peptide hydrolysate [26], we quantified the impact of the
encapsulation processing conditions on bioactivity. Activity of CasHyd in the encapsulated pellets was
determined relative to activity of non-encapsulated CasHyd peptide in the GHSR-1a overexpressing
cells, as described above. Activity was quantified as being 75% for uncoated pellets and 60% for coated
pellets (Figure 11).
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Figure 11. CasHyd retains bioactive functionality after encapsulation. Activity of CasHyd after
encapsulation was determined relative to activity of non-encapsulated CasHyd in GHSR-1a- expressing
cells. Activity was quantified as being 75% for uncoated pellets and 60% for coated pellets
(representative of three independent experiments carried out in triplicate).
2.11. Cumulative Food Intake Studies after Oral Administration of Peptide Encapsulated in
Gastro-Protective Pellets
In food intake studies following an oral gavage of casein hydrolysate encapsulated in a coated
pellet formulation vs. a blank pellet formulation, there were no overall sig ificant increases note
in the amo nt of food intake for males or females; ho ever, a trend towards a overall increase is
noted at the 6 h timepoint for both (Figure 12). A significant increase in amount of food consumed was
observed in the 4–5 h time bin for the male cohort also. However, the orexigenic effect seen after oral
dosing of the unencapsulated peptide is not confirmed here.
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Figure 12. Cumulative food intake following oral administration of gastro-protective pellets 
containing casein-derived hydrolysate. Food (regular chow) intake in male (top) and female (bottom) 
Sprague-Dawley rats was determined following oral gavage with 35 mg kg-1 dose of encapsulated 
CasHyd over 6 h. Cumulative food intake (CFI) was determined at regular intervals, beginning 4 h 
after oral gavage of the coated pellets containing CasHyd, or an equivalent weight of blank pellets 
(A,C) The food intake per time bin is also illustrated (B,D). Graphs represent the mean ± SEM. 
Statistical significance was determined using repeated measures ANOVA and estimation of 
parameters for food intake. Pairwise comparisons were carried out using Tukey’s post-hoc test, while 
an independent samples t-test was used for each individual time bin; statistical significance is 
depicted as * p < 0.05. 
3. Discussion 
The endogenous hormone ghrelin, and its receptor, GHSR-1a, are of vital importance in 
maintaining energy homeostasis and appetite regulation [11,31]. Numerous studies report orexigenic 
effects after administration of the hormone [32,33]. Furthermore, natural analogues of ghrelin have 
provided anecdotal and, more recently, experimental evidence of a positive effect on appetite and 
energy balance in susceptible population groups [18]. Hydrolysates of milk proteins, both casein and 
whey, are increasingly recognised for their bioactive components which may bestow therapeutic 
benefits on appetite [1,2,5,34]. A casein-derived bioactive fraction with specific serotonin-2C receptor 
(5-HT2C) agonist activity eliciting satiating properties in a rodent model has been described [4]. In this 
study, we demonstrated that a casein hydrolysate displayed intrinsic GHSR-1a agonist activity which 
translated to an effect on increasing food intake in vivo in rats. 
The dairy hydrolysate, CasHyd, dose-dependently and specifically increased intracellular Ca2+ 
in HEK293A cells heterologously expressing the GHSR-1a. We have previously reported ghrelin 
agonistic effects of a whey-based protein derivative in the same in vitro system [26]. The CasHyd 
described here displays superior potency (0.27 mg/mL) compared to the whey derived fraction; 
however it is considerably less than the endogenous GHSR-1a ligand (0.25 µg/mL), ghrelin (Figure 
1). This is likely reflective of the fact that CasHyd is a mixture of peptides, only some, or one, of which 
may be active on GHSR-1a. Interestingly, the in vitro activity has negligible effects on WT, 5HTR2C or 
the fully edited form of 5HTR2C. The activity of CasHyd is also shown to be both additive and 
synergistic to native ghrelin in vitro (Figures 5 and 6). Furthermore, the activity of CasHyd was 
assessed in the neuroblastoma cell line, SHSY-5Y, engineered to overexpress the GHS-R1a receptor 
as a native receptor using lentiviral vectors. A calcium mobilisation response following exposure to 
the endogenous ligand ghrelin as well as the dairy-derived hydrolysate was observed in both this 
cell line, and that of HEK293A (Figure 4). This reinforces the GHS-R1a activating potential of the 
hydrolysate. This provides promising evidence to further examine CasHyd activity on GHSR-1a in a 
physiologically relevant environment using primary cultured neuronal cells. HPLC-SEC contrasted 
the size differences of the parent casein protein and CasHyd, confirming the efficacy of the 
hydrolysation process (Figure 3), while HPLC was also used to confirm the reproducibility of the 
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3. Discussion
The endogenous hormone ghrelin, and its receptor, GHSR-1a, are of vital importance in
maintaining energy homeostasis and appetite regulation [11,31]. Numerous studies report orexigenic
effects after administration of the hormone [32,33]. Furthermore, natural analogues of ghrelin have
provided anecdotal and, more recently, experimental evidence of a positive effect on appetite and
energy balance in susceptible population groups [18]. Hydrolysates of milk proteins, both casein
and whey, are increasingly recognised for their bioactive components which may bestow therapeutic
benefits on appetite [1,2,5,34]. A casein-derived bioactive fraction with specific serotonin-2C receptor
(5-HT2C) agonist activity eliciting satiating properties in a rodent model has been described [4]. In this
study, we demonstrated that a casein hydrolysate displayed intrinsic GHSR-1a agonist activity which
translated to an effect on increasing food intake in vivo in rats.
The dairy hydrolysate, CasHyd, dose-dependently and specifically increased intracellular Ca2+ in
HEK293A cells heterologously expressing the GHSR-1a. We have previously reported ghrelin agonistic
effects of a whey-based protein derivative in the same in vitro system [26]. The CasHyd described
here displays superior potency (0.27 mg/mL) compared to the whey derived fraction; however it
is considerably less than the endogenous GHSR-1a ligand (0.25 µg/mL), ghrelin (Figure 1). This is
likely reflective of the fact that CasHyd is a mixture of peptides, only some, or one, of which may
be active on GHSR-1a. Interestingly, the in vitro activity has negligible effects on WT, 5HTR2C or the
fully edited form of 5HTR2C. The activity of CasHyd is also shown to be both additive and synergistic
to native ghrelin in vitro (Figures 5 and 6). Furthermore, the activity of CasHyd was assessed in the
neuroblastoma cell line, SHSY-5Y, engineered to overexpress the GHS-R1a receptor as a native receptor
using lentiviral vectors. A calcium mobilisation response following exposure to the endogenous
ligand ghrelin as well as the dairy-derived hydrolysate was observed in both this cell line, and that of
HEK293A (Figure 4). This reinforces the GHS-R1a activating potential of the hydrolysate. This provides
promising evidence to further examine CasHyd activity on GHSR-1a in a physiologically relevant
environment using primary cultured neuronal cells. HPLC-SEC contrasted the size differences of the
parent casein protein and CasHyd, confirming the efficacy of the hydrolysation process (Figure 3),
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while HPLC was also used to confirm the reproducibility of the hydrolysation process (Figure S2).
The high presence of low molecular weight peptide sequences (<1 kDa, Table 2) is critical to the
bioactivity reported in these assays.
This is the first instance in which a casein-derived peptide has been shown to have GHSR-1a
agonist properties in vitro. Furthermore, an increase in food intake in vivo is reported after dosing with
CasHyd. This may be due to a translation of GHSR-1a stimulation from in vitro to in vivo, although
further studies must be done to confirm this. Nevertheless, we show that CasHyd displays evidence
of enhancing food intake in healthy Sprague-Dawley (SD) rats. Male and female rats treated orally
using a solution of CasHyd at a dose of 50 mg/kg showed a three-fold increase in food intake over
the six-hour experiment (Figure 8); however, this is tempered by a relatively low quantity of food
consumed overall. Time bins illustrate a significant elevation in both groups in the 5–6 h timepoint,
potentially indicative of a prolonged/delayed systemic effect. Interestingly, following IP injection of
CasHyd (50 mg/kg dose), neither male nor female rats displayed a significant increase in food intake
relative to control (Figure 7). The apparent success of oral delivery of the bioactive peptide relative to
injection may be reflective of the distribution of the GHSR-1a in vivo, which is heavily expressed in
the gastrointestinal tract and involved in neuronal signalling to appetite centres in the brain [26].
Despite the apparent increase in food intake after oral gavage of CasHyd, in vitro assays confirm
that acidic pH, comparable to that experienced in the gastric conditions, is detrimental to CasHyd
bioactivity (Figure 9). The ability of bioactive peptides to elicit a beneficial effect in vivo is hence
likely to be highly dependent on the use of a gastro-protective delivery system [35,36]. This is in
line with recent literature highlighting the role of drug-delivery research strategies for bioactive
materials [36,37]. Therefore, we sought to develop a gastro-protective formulation to minimise
acid-mediated degradation of the casein fraction and enhance delivery to the small intestine. A coated
pellet formulation was established, utilising extrusion-spheronisation for pelletisation, followed by
coating with an ethylcellulose-based polymer using fluidised bed technology. CasHyd encapsulated in
a coated oral delivery vehicle (pellets) showed a trend towards an increase in food intake in female rats
(p = 0.054), and male rats (p = 0.097) at the 6-h timepoint, although overall no significant differences are
noted. Furthermore, the absolute amount of food consumed in the experimental period is higher after
dosing with pellets (Figure 12) compared with CasHyd solution (Figure 8), which may be reflective
of the bulk volume of pellets; it may be that dosing pellets which slowly disintegrate in the intestine
creates a paradoxical increase in food intake, thereby confounding any comparisons to orally dosed
solutions. Furthermore, the orally dosed pellets impact on the timing of the release of the bioactive
which may in itself lead to different effects; i.e., the immediate availability of the peptide in the stomach
vs. the gradual release from slowly dissolving pellets.
Overall, although food intake results showed high variability, these initial proof-of-concept studies
represent promising results. The increase in food intake after oral gavage of CasHyd is tempered by
efforts to substantiate the claim as an appetite stimulant by incorporating it into a gastro-protected
vehicle. These efforts did not find any such increase, in either food intake or in the additional blood
biomarkers reported in the supplementary data (Figure 12 and Figure S1). Further discussion on the
study limitations is therefore merited, specifically in relation to the suitability of the experimental
setup for assessing food intake, and peptide release characteristics from the delivery system.
Firstly, although the food intake model described has been reported in previous studies involving
a bioactive peptide, food intake in rodents is inherently variable, and susceptible to change by a
multitude of factors. Inter-experimental variability is evident in the differing absolute amount of food
consumed between studies. Healthy, normophagic rats were used in this study making it difficult to
observe any increases in food intake, given that metabolic drive would generate a healthy appetite by
default. All experiments were also carried out in the light phase, when rodents normally would be
asleep—circadian fluctuations may serve here as a confounder to assessing true appetite. Furthermore,
the dosing procedure exerted a degree of restraint stress upon the animals, while there is a risk of minor
local injury to the oesophagus in gavaged rats which is also likely to impact on food intake. Secondly,
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the bioactive hydrolysate itself is likely to be highly fragile in vivo, due to low gastric pH (discussed
above), as well as intestinal peptidases. Variability in results may well be a consequence of systemic
breakdown. Thirdly, in the case of pelletised CasHyd, the delivery system design incorporated the
peptide into a gastro-protected pellet which exerted a degree of processing stress on the peptide,
resulting in a loss of ~40% bioactivity. The bulk effect of solid pellets also seems to have imparted
a default increase in food intake in both males and females compared to oral solution. While this
formulation was useful as proof of concept, process optimisation is required to minimise activity losses,
reduce bulk volume and tailor the release profile further in vivo.
Despite the above described caveats to this study, hitherto, a lot of evidence substantiating
nutraceutical and bioactive health claims comes from in vitro bioinformatics, with many lacking
tangible in vivo evidence of effect [1,38]. Therefore, evidence is needed to further support the
claim of dairy-derived bioactives for appetite modulation. Our casein-derived bioactive peptide,
CasHyd, shows promising novel results translating a specific in vitro bioactivity with high potency,
to a promising biofunctional effect on food intake in vivo, suggesting overall success of this proof of
concept study. Given a more suitable platform for assessment of food intake, and/or an optimised oral
delivery mechanism to improve stability during formulation, a considerable potential to increase food
intake in vivo by targeting intestinal GHSR-1a exists.
The area of bioactives for appetite modulation is of growing commercial interest and has the
potential to address an unmet clinical need by providing an evidence-based, dietary incorporated,
early intervention for conditions of undereating. CasHyd is a GHSR-1a agonist which represents a
novel nutraceutical approach to increasing appetite in susceptible populations. However, further work
must be done in order to fully elucidate its clinical merit, while technology to retain and enhance
activity in vivo is also required.
4. Materials and Methods
4.1. Materials
Dairy-derived peptide hydrolysate (CasHyd) was provided by Food for Health Ireland (see
Section 2.2). Disposable plastic flexible gavage tubes were purchased from Instech Laboratories (Instech
Laboratories, Inc. Plymouth Meeting, PA, USA). Standard chow (2018S Teklad Global 18% Protein
Rodent Diet) was procured from Harlan, UK Ltd. (Bicester, UK). For encapsulation of the bioactive,
an aqueous pseudo-latex of EC (Surelease® Type B NF) was sourced from Colorcon Corp., Indianapolis,
Indiana. Microcrystalline cellulose (MCC, Avicel® PH-101 NF Ph. Eur.) was purchased from FMC
Corp., Little Island, Cork, Ireland and pharmaceutical grade ethanol 96% (v/v) from Carbon Chemicals
Group Ltd., Ringaskiddy, Cork, Ireland. For the Ca2+ mobilisation assays, fetal bovine serum (3.3%)
was obtained from Sigma-Aldrich, Arklow, Wicklow, F7524, Ireland. The assay buffer was composed
of 1x Hanks balanced salt solution, HBSS, Gibco™ 14065049 (Thermo Fisher Scientific™, Waltham,
MA, USA), containing 20 mM HEPES (Sigma-Aldrich, Arklow, Wicklow, Ireland). The endogenous
agonist, ghrelin (rat), was supplied by Tocris Bioscience, Avonmouth, Bristol, UK (Cat. No. 1465).
4.2. Generation of CasHyd
Sodium caseinate (NaCas, Kerry Group Plc, Listowel, Ireland) was suspended at 10% (w/w) on a
protein basis in water and dispersed under agitation 50 ◦C for 1 h using an in-line mixer (total batch
size—1000 L). Protein hydrolysis was carried through addition of food grade enzyme for a duration
of 3 h at 50 ◦C. The pH of hydrolysis was maintained at a constant pH for the duration of hydrolysis
by addition of a hydroxide base (Microbio, Fermoy, Ireland). The enzyme was then inactivated by
heat treatment through a plate and frame heat exchanger (Unison Engineering Services Ltd., Limerick,
Ireland). Large molecular weight material and aggregates were removed from the hydrolysate through
membrane separation or clarification steps. The clarified material was then ultrafiltered at 50 ◦C using
1 kDa spiral wound organic membranes (Synder Filtration, Vacaville, CA, USA) operating under a
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transmembrane pressure of 2 bar. A diafiltration step using reverse osmosis was utilised in order to
increase recovery of small peptides in the permeate. The permeate fraction (CasHyd) was dried in a
single stage spray dryer (Anhydro F1 Lab Dryer, Copenhagen, Denmark).
4.3. Ca2+ Mobilisation Assay for Peptide GHSR-1a Activity
GHSR-1a mediated changes in intracellular Ca2+ were recorded on a High-Throughput Cellular
Screening System (Molecular Devices Corporation, Sunnyvale, San Jose, CA, USA). Ca2+ mobilisation
assays were performed according to a protocol modified from a previously described method [39].
Stably transfected human embryonic kidney (HEK293A) cells overexpressing GHSR-1a were seeded
in sterile 96-well microtiter plates with black-walled and clear-bottomed wells (3904, Costar, Fisher
Scientific, Dublin, Ireland) at a density of 2.5 × 104 cells per well. Cells were then kept at 37 ◦C in
a humidified atmosphere containing 5% CO2 overnight. Twenty-four hours before the experiment,
the medi was replaced with serum-free media (1% non-essential amino acids). On the day of the assays,
cells were allowed to incubate with 80 µL of 1× Ca5 dye dye (R8186, Molecular Devices) in assay
buffer (1× Hanks balanced salt solution—HBSS, supplemented with 20 mM HEPES buffer). CasHyd
was dissolved in assay buffer (1× HBSS supplemented with 20 mM HEPES buffer). Addition of the
dissolved compounds (25 µL/well) was performed automatically. Fluorescent readings were taken
for 120 s at excitation wavelength of 485 nm and emission wavelength of 525 nm. The percentage
increase in cytosolic Ca2+ was deduced from the difference between basal and maximal fluorescence
and illustrated as a percentage of maximum response (reading from 3.3% fetal bovine serum; FBS).
Background fluorescence from assay buffer alone was subtracted from all readings. The endogenous
agonist ghrelin (1465; Tocris) was also used as a positive control of Ca2+ influx. Data were analysed
using GraphPad Prism software (PRISM 5.0; GraphPAD Software Inc., San Diego, CA, USA). Nonlinear
regression analysis with variable slope was used to generate sigmoidal concentration-response graphs.
4.4. Calcium Imaging
Calcium imaging took place for HEK-GHSR-1a cells seeded on a 12-well plate at 2.0 × 105 cells/mL
two days before the assay according to a previously described method [39]. The day before the assay,
media was swapped to serum-free. For the assay procedure, all media was removed from cells which
were then washed using phosphate-buffered saline and incubated for 1 h at 37 ◦C with 7 µM Fura 2-AM
(F1221, Biosciences) in assay buffer. Upon calcium release, the fluorescent excitation maximum of the
Fura-2 indicator undergoes a blue shift from 363 nm (Ca2+-free) to 335 nm (Ca2+-saturated), while the
fluorescence emission maximum remains unchanged at 510 nm. Upon excitation at 340 nm and 380 nm
respectively, the ratio of the fluorescent intensity emissions at these excitations is correlated to the
levels of intracellular calcium. Subsequently, media was replaced with assay buffer without Fura 2-AM.
Cells were viewed and a field was selected under brightfield illumination (Olympus BX50WI, Tokyo,
Japan). Standard digital epifluorescence system (Cell R, Olympus) was used to measure changes in
intracellular calcium (Ca2+). Light at 340 and 380 nm was generated using a Xenon/Mercury arc burner
(MT20 illumination system, cell R, Olympus), illuminating the cells and stimulating fura 2 fluorescence.
Hydrolysates or the endogenous GHS-R1a receptor agonist ghrelin (SP-GHRL-1, Innovagen, Lund,
Sweden) were added and the excitation spectra at 380 nm (Ca2+-free) and 340 nm (Ca2+-saturated)
with fixed emission at 510 nm were recorded.
4.5. HPLC Characterisation of CasHyd
CasHyd and its parent protein (NaCas) were analysed using size exclusion (SE) high-performance
liquid chromatography using a TSK G2000SWXL 7.8 × 300 mm column (Tosoph Corporation, Tokyo,
Japan). Analysis was carried out at isocratic conditions for 40 min; the mobile phase was 30% v/v and
0.1% v/v TFA in deionised water. Flow rate through the column was 0.5 mL/min. The total injection
volume was 20 mL. Absorbance of the eluate was measured at 214 nm. The following molecular weight
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standards were used for calibration purposes: Tyr-Glu (310 Da); Leu-Trp-Mel-Arg (605 Da); bacitracin
(1.4 kDa); aprotinin (6.5 kDa); α-lactalbumin (14.2 kDa); and, bovine serum albumin (66 kDa).
Different batches of CasHyd were analysed using both reverse-phase (RP) high-performance
liquid chromatography. The HPLC equipment consisted of an Agilent 1200 series chromatograph
(Agilent Technologies, Santa Clara, CA, USA) equipped with an auto-sampler, quaternary pump and a
multiple wavelength detector. RP-HPLC was carried out using a Zorbax 300SB-C18 column (Agilent
Technologies, USA). Two mobile phases were used A: 0.1% v/v tri-fluoro acetic acid (TFA) in deionised
water and B: 0.1% v/v in acetonitrile. A linear solvent gradient was applied, ramping from 3 to 60%
B over 20 mins, 60 to 95% B over the following 4 mins, holding and 95% B for 2 min before a final
decrease from 95 to 3% B over 2 min. Solvent flow rate was 1 mL/min. Solutions (2000 ppm; 15 mL)
were loaded onto the column which was equilibrated at 35 ◦C. The column eluate was monitored at
214 nm.
4.6. Cell Culture, In Vitro Transfection and Lentiviral Transduction
Hek293A and SHSY5Y cells were maintained in culture in high glucose Dulbecco’s modified
Eagle’s medium (Invitrogen, Carlsbad, CA, USA) enriched with heat-inactivated fetal bovine serum
and non-essential amino acids at 10% and 1% respectively, in an atmosphere of 95% air and 5%
CO2 at 37 ◦C. Hek293A cells were transfected using lipofectamine LTX plus reagent (Invitrogen)
with a GHS-R1a-EGFP construct (EX-X0963-M03, Genecopeia, Rockville, MD, USA) according to
manufacturer’s instructions. Cells stably expressing the GHS-R1a receptor with the C-terminal-EGFP
fusion protein, were selectively cultured with geneticin (G418, Merck, Kenilworth, NJ, USA.) as a
selection antibiotic. Those cells showing the greatest fluorescence were sorted using flow assisted cell
sorting (FACS). In addition, SHSY5Y cells were transduced to express the GHS-R1a receptor using a
3rd generation packaging, gene delivery and viral vector production system developed by Naldini
and colleagues [40–43]. HIV-based lentivector (LV) particles expressing the GHS-R1a from a spleen
focus-forming virus (SFFV) promoter in conjunction with an EmGFP sequence expressed as a separate
protein after an internal ribosome entry site (IRES) were generated. Briefly, the GHS-R1a sequence was
cloned into a HIV-based, replication deficient, lentiviral expression plasmid, pHR-SIN-BX-IRES-EmGFP
(kind gift of Adrian Thrasher, Institute of Child Health, London, United Kingdom), modified to
exclude the shRNA U6 promoter. The GHS-R1a gene was amplified, gel isolated using the Qiagen Gel
Extraction Kit (#28706) and ligated into the lentiviral vector using BamHI and XhoI restriction sites,
generating pHR-GHS-R1a-IRES-EmGFP. Lentivector (LV) GHS-R1a expressing particles, pseudotyped
with the vesicular stomatitis virus G (VSV-G) were produced using 293T-17 cell following transient
cotransfection of the cloned expression constructs, pHR-GHS-R1a-IRES-EmGFP, the packaging
construct, pCMV∆R8.91 and the envelope construct, pMD.G –VSVG. SHSY-5Y cells were transduced
with the GHS-R1a expressing lentiviral vectors diluted in transduction media, consisting of DMEM
with 2% heat-inactivated FBS, 1% NEAA and an additional 8µg/mL polybrene® (Sigma; #H9268).
Fluorescence was monitored using flow cytometry as indicator of receptor expression.
4.7. Cumulative Food Intake Studies
Male and female Sprague-Dawley (SD) rats were purchased from Envigo, UK. Rats were 7 to 8
weeks-old upon arrival in the animal unit. Rats were group-housed at 4 per cage in an environment
controlled for light-dark cycle (12-h light; lights on at 7:00 a.m.), temperature (21 ± 1 ◦C) and humidity
(55 ± 10%). Water and standard lab chow (2018S Teklad Global 18% Protein Rodent Diet, Envigo,
Huntingdon, UK) were available ad libitum. All experiments were in full accordance with the
European Community Council directive (86/609/EEC) and approved by the Animal Experimentation
Ethics Committee of University College Cork (B100/3774). Animals were habituated to experimental
conditions for a week prior to experiments taking place. On experimental day, animals were
administered their respective treatment at the onset of the light phase and then placed in individual
cages for duration of food intake monitoring. Food intake was then recorded by weighing the chow
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at defined intervals. For the gastro-protected pellets, animals were food restricted for a period of 4 h
before a pre-weighed quantity of chow was added to the cages. The dosing system for pellets consisted
of a flexible PVC gavage tube which was filled with a pre-weighed quantity of blank or active pellets.
After insertion of the dosing tube a guidewire was used to administer the dose of pellets directly into
the stomach.
4.8. Pellet Preparation by Extrusion-Spheronisation
Requisite quantities of CasHyd and MCC were combined in a ratio of 33:67 and manually blended
for 1 min. A Kenwood planetary mixer (KM005, Kenwood Ltd., Hampshire, UK) was then used
to further dry blend the mixture for 5 min at a minimum agitation setting. The dry powder blend
was gradually wetted by adding deionised H2O, under constant agitation by the planetary mixer.
The granulation end-point was achieved upon addition of a cumulative amount of deionised H2O
equivalent to 45% (w/w) of the dry powder blend. The granulate was immediately extruded at an
extrusion speed of 17–19 rpm using a sieve extruder (Caleva® Extruder 20, Caleva Process Solutions,
Sturminster Newton, UK). Screen thickness and aperture diameter were both 1 mm. The extrudate was
then placed into a Caleva® Spheroniser 250 for 90 s at 1500 rpm (Caleva Process Solutions, Sturminster
Newton, Dorset, UK). Pellets were collected and dried using high flow air in a microfluid bed system
(Vector Corp., Marion, IA, USA) at 40 ◦C for 20 min before coating took place.
4.9. Pellet Film Coating
Film coating was performed in a laboratory scale microfluid bed system in bottom-spray mode.
Nozzle air was set to 16–17 psi and airflow was 310–335 L/min. Coating solution, an 11% (w/w)
aqueous pseudo-latex of EC (Surelease® Type B), was fed at a constant rate (1.0 g/min). Prior to coating,
the Surelease polymer was allowed to homogenise for 30 min under constant agitation. Uncoated
pellets were charged to the coating vessel and pre-heated for 10 min with an inlet air temperature
of 80 ◦C, such that sufficient drying could be obtained of the coating polymer. This was achieved
at an outlet air temperature of ~50 ◦C. The amount of coating polymer required for film coating
was calculated as a theoretical percentage weight gain based on the weight of the uncoated pellets
at the start of coating. The microfluid bed coating system was constantly monitored to ensure that
appropriate air flow and drying was maintained in the coating chamber.
4.10. pH Susceptibility Tests
CasHyd was dissolved in deionised H2O and acidified with HCl to the requisite pH (pH 1, 3, 5
and untreated), using a pH enomenal® 1000 L pH meter and electrode. Acidified CasHyd solutions
were incubated for 30 min under gentle agitation. 50 µL of each sample was removed and added to
950 µL of Ca2+ assay buffer and pH checked to confirm that acidity was neutralised before samples
were added to cells.
4.11. In Vitro Dissolution Studies:
Dissolution testing (USP Type 1) was performed, using a basket-type dissolution apparatus
(DISTEK, Inc., Model 2100C, North Brunswick, NJ, USA). Simulated gastric fluid sine pepsin (SGFsp)
(pH 1.2, 500 mLs) was used as dissolution media. Dissolution bath temperature was kept at 37 ◦C and
50 rpm agitation speed. Sampling was conducted at various timepoints. After each sample an equal
volume of dissolution medium was added to the dissolution vessel to maintain volume at 500 mL.
4.12. Peptide Quantification Assay
The bicinchoninic acid (BCA) assay was performed using a BCA assay kit (Thermo Fisher
Scientific™ Pierce™ BCA Protein Assay, Catalog Number 23225) according to a well-established
method. A 2 mg/mL stock solution of CasHyd in SGFsp was used to prepare a series of dilutions
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for preparation of a standard curve (2, 1, 0.5, 0.25, 0.125, and 0.0625 mg/mL, respectively). 25 µL of
each sample obtained during dissolution testing, and standards were plated on a 96-well plate. After
the dissolution experiment was completed, remaining pellets were removed, crushed, and quantified
as above in order to confirm all peptide was released from the formulation. Working reagent was
prepared by mixing BCA assay Reagent A with BCA assay Reagent B in a ratio of 50:1. The working
reagent (200 µL) was then transferred to each well. The plates were then covered and incubated at
37 ◦C for 30 min. Spectrophotometric analysis was performed at 562 nm and the quantity of peptide in
each sample was quantified from standard curves and expressed as a percentage of total peptide in
the pellets.
4.13. Data Analysis
Data were analysed and graphs generated using GraphPad Prism software and Microsoft Excel
software. For in vitro cell screening and dissolution work, means were the result of at least three
independent experiments performed in triplicate. Calcium mobilisation assays report the standard
error of the mean (SEM) while the dissolution result reports standard deviation (SD). For in vivo food
intake, measurements between groups were analysed using a one-way, repeated measures ANOVA
followed by estimation of parameters. If data were non-spherical as determined by Mauchly’s test
for sphericity, a Huynh-Feldt correction was applied for data analysis. Graphs are expressed as mean
± SEM. Statistical significance was indicated as follows: * indicates p < 0.05; ** indicates p < 0.01 &
*** indicates p < 0.001.
5. Conclusions
This work describes a dairy-derived peptide with potent activity on the GHSR-1a in vitro. In vivo
preclinical studies with this bioactive peptide show its potential to act as an appetite stimulant after
oral administration. CFI was increased three-fold after 6 h in male and female SD rats after a single
oral dose. However, while activity of CasHyd was eliminated following exposure to gastric pH,
administration of CasHyd in a gastro-protected pellet formulation only showed a trend towards
increased food intake in both males and females. Variable results may be reflective of the suboptimal
release of peptide coupled with loss of bioactivity in vivo, and/or potential lack of suitability of the
model to assess subtle appetitive changes in a normophagic rat cohort. Overall, high in vitro efficacy
on the GHSR-1a has translated to evidence of an effect on food intake in vivo. Therefore, we consider
this study a valuable contribution to the growing body of evidence for nutraceuticals and nutraceutical
encapsulation platforms, which will serve as a useful reference for further investigations in preclinical
models of age-related malnutrition or cachexia.
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